These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32292557)

  • 61. Inhibition of spleen tyrosine kinase attenuates psoriasis-like inflammation in mice through blockade of dendritic cell-Th17 inflammation axis.
    Alzahrani KS; Nadeem A; Ahmad SF; Al-Harbi NO; Ibrahim KE; El-Sherbeeny AM; Alhoshani AR; Alshammari MA; Alotaibi MR; Al-Harbi MM
    Biomed Pharmacother; 2019 Mar; 111():347-358. PubMed ID: 30593001
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The 2010 patent landscape for spleen tyrosine kinase inhibitors.
    Moretto AF; Dehnhardt C; Kaila N; Papaioannou N; Thorarensen A
    Recent Pat Inflamm Allergy Drug Discov; 2012 May; 6(2):97-120. PubMed ID: 22292554
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment.
    Kim E; Ten Hacken E; Sivina M; Clarke A; Thompson PA; Jain N; Ferrajoli A; Estrov Z; Keating MJ; Wierda WG; Bhalla KN; Burger JA
    Leukemia; 2020 Jun; 34(6):1588-1598. PubMed ID: 31862959
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Genetic and Pharmacological Dissection of the Role of Spleen Tyrosine Kinase (Syk) in Intestinal Inflammation and Immune Dysfunction in Inflammatory Bowel Diseases.
    Biagioli M; Mencarelli A; Carino A; Cipriani S; Marchianò S; Fiorucci C; Donini A; Graziosi L; Baldelli F; Distrutti E; Costantino G; Fiorucci S
    Inflamm Bowel Dis; 2017 Dec; 24(1):123-135. PubMed ID: 29272492
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Immunotoxicity assessment for the novel Spleen tyrosine kinase inhibitor R406.
    Zhu Y; Herlaar E; Masuda ES; Burleson GR; Nelson AJ; Grossbard EB; Clemens GR
    Toxicol Appl Pharmacol; 2007 Jun; 221(3):268-77. PubMed ID: 17490694
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Inhibition of spleen tyrosine kinase attenuates allergen-mediated airway constriction.
    Moy LY; Jia Y; Caniga M; Lieber G; Gil M; Fernandez X; Sirkowski E; Miller R; Alexander JP; Lee HH; Shin JD; Ellis JM; Chen H; Wilhelm A; Yu H; Vincent S; Chapman RW; Kelly N; Hickey E; Abraham WM; Northrup A; Miller T; Houshyar H; Crackower MA
    Am J Respir Cell Mol Biol; 2013 Dec; 49(6):1085-92. PubMed ID: 23889698
    [TBL] [Abstract][Full Text] [Related]  

  • 67. B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies.
    Puri KD; Di Paolo JA; Gold MR
    Int Rev Immunol; 2013 Aug; 32(4):397-427. PubMed ID: 23886342
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Identification of new dual spleen tyrosine kinase (Syk) and phosphoionositide-3-kinase δ (PI3Kδ) inhibitors using ligand and structure-based integrated ideal pharmacophore models.
    Kaur M; Silakari O
    SAR QSAR Environ Res; 2016 Jun; 27(6):469-99. PubMed ID: 27431536
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A PREVIOUSLY UNKNOWN UNIQUE CHALLENGE FOR INHIBITORS OF SYK ATP-BINDING SITE: ROLE OF SYK AS A CELL CYCLE CHECKPOINT REGULATOR.
    Uckun FM; Ma H; Ozer Z; Goodman P; Zhang J; Qazi S
    EBioMedicine; 2014 Nov; 1(1):16-28. PubMed ID: 25506060
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy.
    Baker M; Chaichian Y; Genovese M; Derebail V; Rao P; Chatham W; Bubb M; Lim S; Hajian H; Gurtovaya O; Patel U; Tumlin J
    RMD Open; 2020 Dec; 6(3):. PubMed ID: 33380521
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Identification and characterization of early human photoreceptor states and cell-state-specific retinoblastoma-related features.
    Shayler DWH; Stachelek K; Cambier L; Lee S; Bai J; Reid MW; Weisenberger DJ; Bhat B; Aparicio JG; Kim Y; Singh M; Bay M; Thornton ME; Doyle EK; Fouladian Z; Erberich SG; Grubbs BH; Bonaguidi MA; Craft CM; Singh HP; Cobrinik D
    bioRxiv; 2024 Aug; ():. PubMed ID: 38915659
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Various synthesis and biological evaluation of some tri -tetra-substituted imidazoles derivatives: A review.
    Hamdi A; Daoudi W; Aaddouz M; Azzouzi M; Amhamdi H; Elyoussfi A; Aatiaoui AE; Verma DK; Abboud M; Ahari M
    Heliyon; 2024 May; 10(10):e31253. PubMed ID: 38803909
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Discovery of Sovleplenib, a Selective Inhibitor of Syk in Clinical Development for Autoimmune Diseases and Cancers.
    Jia H; Deng W; Hao B; Cai M; Guo D; Cai Y; Dai X; Wu Z; He W; Wang J; Wang G; Xia S; Li N; Su W; Dai G
    ACS Med Chem Lett; 2024 May; 15(5):595-601. PubMed ID: 38746892
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A comprehensive review of discovery and development of drugs discovered from 2020-2022.
    Shareef U; Altaf A; Ahmed M; Akhtar N; Almuhayawi MS; Al Jaouni SK; Selim S; Abdelgawad MA; Nagshabandi MK
    Saudi Pharm J; 2024 Jan; 32(1):101913. PubMed ID: 38204591
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Signaling pathways regulating the extracellular digestion of lipoprotein aggregates by macrophages.
    Steinfeld N; Ma CJ; Maxfield FR
    Mol Biol Cell; 2024 Jan; 35(1):ar5. PubMed ID: 37910189
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Oxetanes in Drug Discovery Campaigns.
    Rojas JJ; Bull JA
    J Med Chem; 2023 Sep; 66(18):12697-12709. PubMed ID: 37676858
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Spleen tyrosine kinase (SYK) signals are implicated in cardio-cerebrovascular diseases.
    Li M; Wang P; Zou Y; Wang W; Zhao Y; Liu M; Wu J; Zhang Y; Zhang N; Sun Y
    Heliyon; 2023 May; 9(5):e15625. PubMed ID: 37180910
    [TBL] [Abstract][Full Text] [Related]  

  • 78. 3D-QSAR-Based Pharmacophore Modeling, Virtual Screening, and Molecular Dynamics Simulations for the Identification of Spleen Tyrosine Kinase Inhibitors.
    Kumar V; Parate S; Danishuddin ; Zeb A; Singh P; Lee G; Jung TS; Lee KW; Ha MW
    Front Cell Infect Microbiol; 2022; 12():909111. PubMed ID: 35846777
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren's syndrome: a randomized, phase 2, double-blind, placebo-controlled study.
    Price E; Bombardieri M; Kivitz A; Matzkies F; Gurtovaya O; Pechonkina A; Jiang W; Downie B; Mathur A; Mozaffarian A; Mozaffarian N; Gottenberg JE
    Rheumatology (Oxford); 2022 Nov; 61(12):4797-4808. PubMed ID: 35377447
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Immunomodulatory drug discovery from herbal medicines: Insights from organ-specific activity and xenobiotic defenses.
    Shi J; Weng JH; Mitchison TJ
    Elife; 2021 Nov; 10():. PubMed ID: 34779403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.